Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Cardiology

Building Your Foundation: Understanding Infective Endocarditis

At a Glance

Infective endocarditis is a serious infection of the heart valves or inner heart lining. It occurs when bacteria enter the bloodstream and attach to damaged areas, forming growths called vegetations. Early diagnosis and treatment by a specialized medical team are critical for a full recovery.

Infective endocarditis (IE) is a serious infection of the inner lining of your heart chambers and valves (the endocardium) [1]. While hearing this diagnosis can be overwhelming, understanding how the infection works and how modern medicine treats it is the first step toward recovery.

How the Infection Develops

The hallmark of IE is the formation of a vegetation. You can think of a vegetation as a microscopic “nest” where germs hide and grow. It typically forms in a multi-step process:

  1. Surface Preparation: The smooth lining of the heart or a valve becomes slightly roughened or damaged. This can happen due to age, turbulence in blood flow, or the presence of medical hardware [2][3].
  2. The “Sticky” Foundation: To heal the site, your body sends platelets (cells that help blood clot) and fibrin (a protein that acts like biological glue) to the area [1].
  3. Bacterial Hijacking: If bacteria or fungi enter your bloodstream, they can stick to this fibrin-platelet foundation. They then build a protective shield around themselves, often called a biofilm, which makes it harder for your immune system and antibiotics to reach them [1][4].
  4. Growth: As more bacteria, platelets, and immune cells (like neutrophils) pile on, the vegetation grows. These growths can interfere with how your heart valves open and close [1][4].

Who is Most at Risk?

The “face” of endocarditis has changed in recent years. While it once primarily affected people with certain heart defects from birth, it is increasingly seen in older adults and those with modern heart interventions [5][3]. Major risk factors now include:

  • Prosthetic Valves: Artificial heart valves are currently the largest high-risk group [2].
  • Heart Devices: Pacemakers and defibrillators (often called CIEDs) can provide a surface where bacteria can settle [6][7].
  • Recent Procedures: Procedures like TAVR (Transcatheter Aortic Valve Replacement) have been associated with a higher risk of IE compared to some traditional surgeries [8].
  • Vulnerable Populations: People with a history of intravenous drug use or those with chronic conditions like rheumatic heart disease remain at high risk [9][10].

Understanding the Severity

Endocarditis is a high-stakes condition that requires immediate and intensive medical attention. In-hospital mortality rates—the percentage of patients who pass away during their initial stay—are currently estimated between 15% and 20% [11][12]. Looking further ahead, the 5-year mortality rate can be approximately 40% [12].

These numbers reflect the serious nature of the infection, particularly when caused by aggressive bacteria like Staphylococcus aureus [13][14]. However, these statistics also highlight why early diagnosis is so critical: delays in starting treatment are directly linked to higher risks [15].

The Power of the Endocarditis Team

Because IE is so complex, current medical guidelines strongly recommend that you be cared for by a multidisciplinary Endocarditis Team [16][17]. This is a group of specialists who work together to manage your care, usually including:

  • Cardiologists: Heart specialists who monitor your heart function and valve health.
  • Infectious Disease Specialists: Experts who determine exactly which germ is causing the infection and which antibiotics will be most effective.
  • Cardiac Surgeons: Experts who can determine if and when surgery is needed to repair a valve or remove an infection [18][19].

Research shows that patients treated by these specialized teams often have a better prognosis and better adherence to life-saving treatment protocols [20][21]. If surgery is required, it is often a protective step that improves long-term survival by physically removing the source of the infection [22][23].

While the road to recovery can be long, often involving weeks of intravenous antibiotics, the combined expertise of a dedicated team is your strongest asset in fighting this infection.

Common questions in this guide

What is a vegetation in infective endocarditis?
A vegetation is a microscopic growth on your heart valve made up of bacteria, platelets, and immune cells. It acts like a protective shield for the germs, making it harder for your body's immune system and antibiotics to clear the infection.
Who is most at risk for developing infective endocarditis?
People with artificial heart valves, pacemakers, or defibrillators are currently at the highest risk. Other risk factors include recent heart procedures, a history of intravenous drug use, or chronic conditions like rheumatic heart disease.
Why do I need an Endocarditis Team for my treatment?
Infective endocarditis is a highly complex condition that requires coordinated care from different medical experts. An Endocarditis Team typically includes cardiologists, infectious disease specialists, and cardiac surgeons who work together to optimize your treatment and improve your overall prognosis.
Will I need surgery to treat my heart valve infection?
Surgery may be necessary to physically remove the infection or repair a damaged valve, especially if antibiotics alone are not working. Your care team will monitor the size of the vegetations and your heart function to determine if and when surgery is the best step for your recovery.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Do we have an 'Endocarditis Team' here, and which specialists (like infectious disease or cardiac surgery) are on it?
  2. 2.What specific bacteria or fungi were found in my blood, and how does that influence my treatment plan?
  3. 3.Is my infection on a natural heart valve or on a piece of hardware like a prosthetic valve or pacemaker?
  4. 4.Based on my current imaging, how large or mobile are the vegetations on my heart valve?
  5. 5.What are the signs that I might need surgery sooner rather than later?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Neutrophil Extracellular Traps Enhance Staphylococcus Aureus Vegetation Formation through Interaction with Platelets in Infective Endocarditis.

    Hsu CC, Hsu RB, Ohniwa RL, et al.

    Thrombosis and haemostasis 2019; (119(5)):786-796 doi:10.1055/s-0039-1678665.

    PMID: 30731490
  2. 2

    Risk of infective endocarditis after left-sided surgical valve replacement.

    Cahill TJ, Prendergast BD

    European heart journal 2018; (39(28)):2676-2678 doi:10.1093/eurheartj/ehy143.

    PMID: 29584864
  3. 3

    Infective Endocarditis: A Contemporary Review.

    Hubers SA, DeSimone DC, Gersh BJ, Anavekar NS

    Mayo Clinic proceedings 2020; (95(5)):982-997 doi:10.1016/j.mayocp.2019.12.008.

    PMID: 32299668
  4. 4

    Streptococcus gordonii type VII secretion system substrate EsxA induces neutrophil extracellular trap formation in infective endocarditis.

    Hsu CC, Chuang YC, Hsu RB, et al.

    Scientific reports 2025; (15(1)):43708 doi:10.1038/s41598-025-27543-3.

    PMID: 41387757
  5. 5

    Temporal trends in the incidence of infective endocarditis in patients with a prosthetic heart valve.

    Hadji-Turdeghal K, Jensen AD, Bruun NE, et al.

    Open heart 2023; (10(1)) doi:10.1136/openhrt-2023-002269.

    PMID: 37028912
  6. 6

    The role of multimodal imaging in the diagnosis of prosthetic valve and intracardiac device endocarditis: A review.

    Daniel E, El-Nayir M, Ezeani C, et al.

    The international journal of cardiovascular imaging 2025; (41(3)):409-417 doi:10.1007/s10554-024-03277-7.

    PMID: 39585526
  7. 7

    Delayed left anterior mitral leaflet perforation and infective endocarditis after transapical aortic valve implantation-Case report and systematic review.

    Amat-Santos IJ, Cortés C, Varela-Falcón LH

    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2017; (89(5)):951-954 doi:10.1002/ccd.26410.

    PMID: 26775197
  8. 8

    Infective endocarditis and cardiac events after transcatheter vs surgical aortic valve replacement: A nationwide cohort study.

    Kutz A, Purtak M, Laager R, et al.

    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2025; (159()):108011 doi:10.1016/j.ijid.2025.108011.

    PMID: 40784589
  9. 9

    Contemporary cohort study in adult patients with infective endocarditis.

    de Carvalho MGB, de Almeida TVPA, Feijóo NAP, et al.

    The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 2025; (29(3)):104521 doi:10.1016/j.bjid.2025.104521.

    PMID: 40179626
  10. 10

    Sex Differences in Characteristics of Patients with Infective Endocarditis: A Multicenter Study.

    Bhandari R, Tiwari S, Alexander T, et al.

    Journal of clinical medicine 2022; (11(12)) doi:10.3390/jcm11123514.

    PMID: 35743584
  11. 11

    Temporal trends in incidence, patient characteristics, microbiology and in-hospital mortality in patients with infective endocarditis: a contemporary analysis of 86,469 cases between 2007 and 2019.

    Becher PM, Goßling A, Fluschnik N, et al.

    Clinical research in cardiology : official journal of the German Cardiac Society 2024; (113(2)):205-215 doi:10.1007/s00392-022-02100-4.

    PMID: 36094574
  12. 12

    [Complications and prognosis of infective endocarditis].

    Selton-Suty C, Goehringer F, Venner C, et al.

    Presse medicale (Paris, France : 1983) 2019; (48(5)):532-538 doi:10.1016/j.lpm.2019.04.002.

    PMID: 31056233
  13. 13

    Temporal Changes, Patient Characteristics, and Mortality, According to Microbiological Cause of Infective Endocarditis: A Nationwide Study.

    Østergaard L, Voldstedlund M, Bruun NE, et al.

    Journal of the American Heart Association 2022; (11(16)):e025801 doi:10.1161/JAHA.122.025801.

    PMID: 35946455
  14. 14

    Temporal Trends, Characteristics, and Outcomes of Infective Endocarditis After Transcatheter Aortic Valve Replacement.

    Del Val D, Abdel-Wahab M, Linke A, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2021; (73(11)):e3750-e3758 doi:10.1093/cid/ciaa1941.

    PMID: 33733675
  15. 15

    Delayed Diagnosis of Infective Endocarditis-Analysis of an Endocarditis Network.

    Saha S, Zauner B, Kaiser R, et al.

    Journal of clinical medicine 2026; (15(3)) doi:10.3390/jcm15030924.

    PMID: 41682607
  16. 16

    [Contribution of the new guidelines for the management of infective endocarditis].

    Selton-Suty C, Duval X, Hoen B

    La Revue du praticien 2017; (67(2)):183-190.

    PMID: 30512855
  17. 17

    Effect of Publicly Reported Aortic Valve Surgery Outcomes on Valve Surgery in Injection Drug- and Non-Injection Drug-Associated Endocarditis.

    Kimmel SD, Walley AY, Linas BP, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2020; (71(3)):480-487 doi:10.1093/cid/ciz834.

    PMID: 31598642
  18. 18

    Multimodality Imaging in Infective Endocarditis: An Imaging Team Within the Endocarditis Team.

    Erba PA, Pizzi MN, Roque A, et al.

    Circulation 2019; (140(21)):1753-1765 doi:10.1161/CIRCULATIONAHA.119.040228.

    PMID: 31738598
  19. 19

    Neurological Complications of Infective Endocarditis.

    Sotero FD, Rosário M, Fonseca AC, Ferro JM

    Current neurology and neuroscience reports 2019; (19(5)):23 doi:10.1007/s11910-019-0935-x.

    PMID: 30927133
  20. 20

    [Global and national trends in the evolution of infective endocarditis].

    Kobalava ZD, Kotova EO

    Kardiologiia 2023; (63(1)):3-11 doi:10.18087/cardio.2023.1.n2307.

    PMID: 36749195
  21. 21

    Early surgery determines prognosis in patients with infective endocarditis: outcome in patients managed by an Endocarditis Team-a prospective cohort study.

    Pecoraro AJK, Herbst PG, Janson JT, et al.

    Cardiovascular diagnosis and therapy 2022; (12(4)):453-463 doi:10.21037/cdt-21-590.

    PMID: 36033220
  22. 22

    Infective endocarditis at a tertiary care hospital in South Korea.

    Kim JH, Lee HJ, Ku NS, et al.

    Heart (British Cardiac Society) 2021; (107(2)):135-141 doi:10.1136/heartjnl-2020-317265.

    PMID: 33033067
  23. 23

    Multivariate and survival analysis of prognosis and surgical benefits in infective endocarditis.

    Song TX, Sun YD, Zhang B, et al.

    Scandinavian cardiovascular journal : SCJ 2025; (59(1)):2429994 doi:10.1080/14017431.2024.2429994.

    PMID: 39718350

This page provides an overview of infective endocarditis for educational purposes only and does not replace professional medical advice. Always consult your cardiologist or Endocarditis Team regarding your specific diagnosis and treatment plan.

Get notified when new evidence is published on Infective endocarditis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.